Truist Securities Assumes Regeneron Pharmaceuticals at Buy, Lowers Price Target of $798

Benzinga · 11/24/2025 18:18
Truist Securities analyst Gregory Renza assumes Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy rating and lowers Price Target of $798.